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Background. The challenging treatment of penetrating paediatric Crohn’s disease (CD) involves pharmacological and surgical
approaches. Despite a proved eﬃcacy of anti-TNF agents for treatment of complex fistula, a large number of patients cannot
achieve a complete healing and relapse during the followup. Aim. We report a paediatric case with CD and colonic perforation
who was successfully treated with medical therapy only, including anti-TNFα. Case Presentation. During a colonoscopy performed
on a 9-year-old girl with CD, a perforation occurred in correspondence of a fistula at the colonic splenic flexure. The formation of
a collection was then detected (US, enteric-CT), as well as a fistula connecting the colon to the collection. The girl was kept fasting
and treated with total parenteral nutrition and antibiotic therapy. Treatment with Infliximab was also started, and after the third
dose a US control showed disappearance of the collection and healing of the enteric fistula. Parenteral nutrition was progressively
substituted with enteral feeding, and no surgical treatments were needed.Discussion. In pubertal children with penetrating CD, the
option of an eﬃcacious medical treatment to avoid amajor surgical approach on the bowel is to be aimed for growth improvement.
This approach requires a strictly monitored long-term followup.
1. Introduction
Many recent studies on therapeutic availabilities for inflam-
matory bowel disease (IBD) have evidenced that a top-down
treatment for the more aggressive phenotypes of disease
relates to a better outcome and is associated with a prolonged
remission within the long-term followup. This approach can
reduce the need of multiple further treatments. It is crucial
to identify those patients who deserve a top-down approach
in order to sustain their growth and pubertal development
until and throughout adolescence [1–3].
A surgical intervention is generally to be considered as a
last option for IBD; nevertheless it happens to be required
in 50–70% of cases with Crohn’s disease (CD) within 10–15
years since diagnosis [4–6].
The ineﬃcacy of medical treatment in controlling the
activity of disease in IBD patients with unacceptable quality
of life is the most common indication to a surgical interven-
tion [7, 8].
We here report the case of a young girl with penetrating
CD and formation of a perisplenic and retrocolonic col-
lection, who responded successfully to a medical treatment
including anti-TNF-alphas and was able to avoid surgical
intervention, with a subsequent brilliant recuperation in
linear weight and pubertal growth as well as in quality of life.
2. Case Presentation
The clinical history of a caucasian 9-year-old girl began with
the appearance of diﬀuse abdominal pain, fatigue, anorexia,
and progressive weight loss.
As these symptoms had been worsening throughout
the following six months, a diagnostic upper and lower
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Figure 1: Axial (a) and Coronal (b) abdominal CT projections
(with enteric contrast) demonstrate a perisplenic hydroaerial
collection with a dense component compatible with enteric content
(arrows). A thin fistula (∗) connects the collection to the colonic
lumen. A further retroperitoneal fluid collection is detectable at the
left parietal-colonic region.
endoscopy was performed: multiple ulcers, adherent fibrin,
and pseudopolyps were observed at the transverse colon
and left colon. The Bauhin valve was stenotic. Superficial
ulcers and erosions were seen also at the terminal ileum. The
histological exam confirmed a pattern being compatible with
CD.
The endoscopic procedure was complicated by a perfora-
tion at the level of the splenic colonic flexure, which required
an urgent laparoscopic treatment with suture of the colonic
wall. During the subsequent followup, the formation of a
perisplenic collection was detected at ultrasound (US) and
CT, with concomitant increase in the pancreatic enzymes.
After an initial improvement in the clinical general
conditions with parenteral antibiotic treatment, a severe
abdominal pain reappeared with main localisation on the
left side, together with fever, leucocytosis, and increase in
inflammation indexes (CRP 120mg/L). An intensification of
the immunosuppressive treatment was therefore performed
adding Azathioprine to the ongoing corticosteroid therapy.
An abdominal CT performed (Figure 1) evidenced a
perisplenic hydroaerial collection with a dense component
which was compatible with enteric content; a thin fistula
connecting the collection to the colonic lumen was also
depicted, as well as a further retroperitoneal fluid collection
at the left parietal-colonic region.
(a)
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Figure 2: Axial abdominal CT projections (with enteric contrast
enhancement) showing a progressive healing of the fistula connect-
ing the colonic lumen to the collection before (a) and after (b)
the second administration of anti-TNF-α. Figure 2(a). detects the
passage of enteric contrast from the colon into the parietal-colonic
collection, which is no more visible in Figure 2(b).
Ten days later, the child was transferred to our Unit of
Paediatric Gastroenterology appearing febrile, undernour-
ished, and in compromised conditions.
The anatomical characteristics of the collection and the
diagnosis of active CD determined major surgical concerns
for a selective drainage. A surgical alternative proposed was
total colectomy with ileostomy.
We decided instead to choose a medical treatment which
initially consisted in long-term parenteral antibiotic therapy,
parenteral nutrition, and complete fasting. Azathioprine and
corticosteroid treatment were suspended.
A close monitoring of the collection and of the fistula was
performed through CT (Figure 2) and US images.
The child progressively recovered better clinical con-
ditions with disappearance of fever, abdominal pain, and
decrease in inflammation indexes and pancreatic enzymes.
A first attempt with enteral nutrition evidenced an
increase in the dimensions of the abdominal mass at a
US control, due to the passage of the intestinal content
through the fistula until the reaching of the perisplenic and
retroperitoneal region where the previous collection was still
located.
A complete fasting was thus indicated.
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A progressive improvement in general condition and
nutritional status, together with a gradual reduction in the
dimensions of the abdominal collection until the disappear-
ance of its parietal-colonic component was observed.
After onemonth of treatment, keeping a complete fasting
and the parenteral antibiotic therapy, a minimal perisplenic
collection and a thin colonic fistula were still detectable;
a first dose of anti-TNF-alpha (Infliximab 5mg/Kg) was
administered attesting good toleration without any adverse
eﬀect. The subsequent radiologic controls evidenced a major
reduction in the dimensions of the perisplenic collection,
(2× 1.5 cm) and the absence of any passage of the oral mean
of contrast (Gastrographin) through the fistula.
At this point, after one month and a half since the admis-
sion at our Unit, the child was allowed to introduce orally
a small amount of exclusive polymeric formula and liquids.
No complications were attested until the administration of
the second dose of Infliximab (2 weeks after the first dose).
The subsequent radiological controls evidenced a com-
plete disappearance of the fistula as well as of the perisplenic
collection.
The child did not present any clinical symptom. Her
nutritional condition at discharge was significantly improved
with a gain of 4 kilograms in body weight in 2 months.
The girl is now proceeding with anti-TNF-alpha treatment
and has completely suspended parenteral nutrition since one
month and a half after discharge. Her height and body weight
are now both corresponding to the 50∧ percentile for age.
The child refers an excellent quality of life.
3. Discussion
The anti-TNF-α Infliximab is at present the only proved drug
to be able to modify the natural history of IBD [1, 3, 4, 9, 10].
Infliximab eﬃcacy for induction and maintenance of
remission in children and adults with severe penetrating
Crohn’s disease who are nonresponders to the conventional
therapy, is observed in terms of mucosal healing, decrease
in incidence of complications and hospitalisations, improve-
ment in extraintestinal manifestations and, above all, in the
process of child growth [1, 3, 9]. The eﬃcacy of Infliximab
is usually more observed within the paediatric population
than among adult patients, as regards both the induction and
maintenance of remission. Nevertheless, any adverse eﬀect of
anti-TNF-α treatment is less tolerated among children who
present more problems related to adverse eﬀects and reduced
compliance [11].
It is evidenced that in children and adolescents with
growth delay, treatment with Infliximab reestablishes the
normal linear growth rate and can also recuperate the
pubertal development.
The presence of nonperianal fistula (i.e., enteric-enteric,
enteric-cutaneous, and enteral-urinary) significantly reduces
the response to biological treatment (which decreases
to about 20%), probably because for these lesions the
mechanical component predominates on the inflammatory
component; the surgical solution can therefore be the unique
eﬃcacious alternative for these cases [4, 5].
A surgical intervention represents a psychologically
important step to be faced by young patients and their
families; an appropriate counselling and a psychological
preparation is determinant to increase patients’ copying [4].
The morbidity related to active IBD and its progression
needs to be balanced against the morbidity of a surgical
intervention.
Crohn’s disease potentially involves the whole gastroin-
testinal tract, so a surgical intervention does not represent a
curative solution since the disease may relapse in any other
remaining part of the bowel. The risk for relapse is generally
higher for the perforating phenotype than for the stenosing
one. One year after surgery, 75% of patients presents new
lesions at the endoscopic evaluation whereas a 40–53%
presents relapses for which a new surgical intervention is
needed [1].
What arises from this clinical experience are the potential
benefits of a medical approach (including anti-TNF alpha) in
cases of paediatric complicated penetrating CD. In pubertal
children with IBD, the option of an eﬃcacious medical
treatment with avoidance or postposition of a major surgical
approach on the bowel (i.e., colectomy, ileostomy) is to be
aimed for growth improvement.
This approach requires a strictly monitored long-term
followup.
We consider this case experience a significant proof of the
potentialities of a well-conducted medical therapy for those
severe cases of IBD with an unfavourable risk-benefit balance
for surgical options.
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